Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT) in patients implanted with the Resolute Onyx Drug-Eluting Stent (DES)...
Stents Drug Eluting
-
-
May 1, 2017 — The U.S. Food and Drug Administration (FDA) approved Medtronic’s Resolute Onyx Drug-eluting Stent (DES).
-
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent. It was cleared by the FDA and launched into the U.S. market May 1, 2017.
-
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new BioFreedom Pivotal Study. The study will be conducted under an Investigational...
News | Stents Drug Eluting | September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and...
News | Antiplatelet and Anticoagulation Therapies | August 18, 2017
August 18, 2017 — Medtronic plc announced a global randomized...
News | Antiplatelet and Anticoagulation Therapies | August 03, 2017
August 3, 2017 — Abbott recently announced the first patient has been enrolled in a...
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion...
News | Stents Drug Eluting | May 12, 2017
May 12, 2017 — PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial...
Technology | Stents Drug Eluting | May 01, 2017
May 1, 2017 — The U.S. Food and Drug Administration (FDA) approved Medtronic’s Resolute Onyx Drug-eluting Stent (DES...
Videos | Stents Drug Eluting | May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent. It was cleared by the FDA and...
News | Stents Drug Eluting | March 03, 2017
March 3, 2017 — Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS...
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc. first-in-class Cobra...
Blog | Stents | February 13, 2017
Stents were the key focus of interventional cardiology for more than 20 years, but the focus has changed in recent...
Blog | January 30, 2017
DAIC has worked hard to bring useful technology news and resources to our readers. While we conduct reader surveys...
The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.
Feature | Stents Bioresorbable | January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable...
An OCT image showing good stent strut apposition against the vessel wall.
News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (...
Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.
Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the...
News | Stents Drug Eluting | January 10, 2017
January 10, 2017 — Medinol announced in December positive twelve-month clinical results from the BIONICS study. The...
